QualityDipStocks / Health Care · Medical/Nursing Services
Aveanna Healthcare AVAH
Outside our quality screen, so we don’t track its dips. It’s 9% below its 52-week high.
Outside our quality screen. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- $13.00price +1%
- Off 52-wk high
- −9%
- Risk vs market
- Lowbeta 0.59
4 bullish · 5 bearish See why
Repriced or dip?
Near its high
The price is 9% below its 52-week high (Sep 14), but the business held up: shares outstanding fewer shares, each owns more, net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts.
Some numbers held up (shares outstanding fewer shares, each owns more, net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts), others slipped. The price is 9% below its 52-week high.
The price is 9% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
52-wk high: P/E 11.8×; 52-wk low: P/E 5.9×; now: P/E 10.6×.
| High | Low | Now | |
|---|---|---|---|
| Price | $14.38Sep 14 | $6.22Apr 10 | $13.12 |
| Implied growth | n/a | n/a | n/a |
| P/E | 11.8× | 5.9× | 10.6× |
| EV/Sales | 1.7× | 1.0× | 1.6× |
What this means: a lower P/E than at the high means you pay less for each dollar of profit than buyers did then.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for AVAH: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much AVAH moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 3.8× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.59
- Volatility
- 48% vs 13% SPY
- Correlation SPY
- 0.15
- Correlation QQQ
- 0.08
How it ranks
Where AVAH stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 4 measures
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+20% · vs the 12 months beforeTop 27%of 1,814
- Operating margin11% · of sales kept as operating profitLowest 45%of 1,288
- Return on invested capital18% · profit per dollar of capitalTop 25%of 838
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $13.00 · FCF value $11.31
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ProfitabilityOperating margin widened to 10.5% in FY2026 from 0.4% in FY2023 (SEC filings).
ValuationP/E of 10.6× vs a 29.0× median for the 135 Health Care companies we cover.
GrowthSales grew 20% to $2.6B over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityReturn on invested capital of 18%, above the 9.5% discount rate our DCF uses.
Top bearish points 5 of 5
Balance sheetOperating income covers interest only 2.2× over the last 12 months.
Balance sheetDebt is 4.5× shareholders’ equity.
Cash returnsShare count up 6.9% in a year: existing holders are being diluted.
Balance sheetNet debt of $1.2B, 41% of the market cap (Jul 4, 2026).
QualityDoesn’t pass our quality screen: net debt 4.5× EBITDA (limit 3×).
All fundamentals
P/E 10.6 · ROE 200% · Sales +20%
Valuation
- P/E
- 10.6×Health Care median 29.0×
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- 14.4×
- Price / sales
- 1.11×
- Price / book
- 10.09×
- Market cap
- $2.9Blisted
- Enterprise value
- $4.1B
Growth
- Revenue, 12 months
- $2.6B
- Sales growth, 12 months
- +19.5%vs the 12 months before
- Sales growth, 3 yrs
- +10.8%/yrfrom FY2022
- Diluted EPS, 12 months
- $1.26
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $275M
- Net income growth
- n/an/m: earnings a year ago near zero
Profitability
- Gross margin
- 32.3%
- Operating margin
- 10.5%
- Net margin
- 10.6%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- 200%
- Return on invested capital
- 18%
Balance sheet
- Cash & short-term inv.
- $97M
- Total debt
- $1.3B
- Net cash
- −$1.2B
- Debt / equity
- 4.52×
- Interest coverage
- 2.2×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +6.9%diluted shares vs a year ago
- Stock-based comp
- $17M
Trailing 12 months to Jul 4, 2026; balance sheet at Jul 4, 2026. From Aveanna Healthcare’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.1B · Sales +14%
- Free cash flow, 12 months$0.1B
- Free-cash-flow yield3.4%
- Free-cash-flow margin4%
- Gross margin32%
- Operating margin13%
- Return on invested capital15%
- Return on equity199%
- Sales growth (latest quarter vs year-ago quarter)+14%
- Net debt / EBITDA4.5×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $13.12
- 52-wk lowlowest close, 1 year$6.22−52.6%
- Market Valueavg paid since Aug 13$13.00−0.9%
- PriceMon Nov 2 close$13.12you are here
- 52-wk highhighest close, 1 year$14.38+9.6%
Momentum & 52-week range
RSI 55 · 5 days −0.5%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 12
- DateThu Nov 12, before the open
- Consensus EPS$0.19
- Year-ago EPS$0.12
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
AVAH is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Aveanna Healthcare in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Medical/Nursing Services
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.